Urol. praxi, 2012; 13(4): 163-166

Noncancer late sequelae treatment for testicular germ cell tumours

MUDr.Tomáš Büchler, Ph.D., MUDr.Jana Grimová, MUDr.Pavla Umhöhová, MUDr.Lucie Žitňanská, prof.MUDr.Jitka Abrahámová, DrSc.
Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

The cure rate of testicular germ cell tumours is among the highest of all malignancies. However, therapy for TGN leads to an increased risk

of various long-term complications including neurotoxicity, cardiotoxicity, endocrine disturbances, and fertility problems. Awareness,

screening and timely therapy for these complications can decrease morbidity and mortality in this population.

Keywords: testicular tumours, late sequelae, neurotoxicity, cardiotoxicity, fertility

Published: August 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Büchler T, Grimová J, Umhöhová P, Žitňanská L, Abrahámová J. Noncancer late sequelae treatment for testicular germ cell tumours. Urol. praxi. 2012;13(4):163-166.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrahámová J, Povýšil C, Dušek L, a kolektiv. Nádory varlat. Grada, Praha 2008.
    2. Meinardi MT, Gietema J, Van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000; 18: 1725-1732. Go to original source... Go to PubMed...
    3. Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol. 2005; 23: 3718-3725. Go to original source... Go to PubMed...
    4. Nord C, Fossa SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer. 2003; 88: 36-41. Go to original source... Go to PubMed...
    5. Sagstuen H, Aass N, Foss? SD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23: 4980-4990. Go to original source... Go to PubMed...
    6. Huddart RA, Norman M, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003; 21: 1513-1523. Go to original source... Go to PubMed...
    7. van den Belt-Dusebout AW, Nuver J, deWit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006; 24: 467-475. Go to original source... Go to PubMed...
    8. Foss? SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007 Apr 4; 99(7): 533-544. Go to original source... Go to PubMed...
    9. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003 Apr 15; 21(8): 1513-1523. Go to original source... Go to PubMed...
    10. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010 Oct 20; 28(30): 4649-4657. Go to original source... Go to PubMed...
    11. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000 Apr; 18(8): 1725-1732. Go to original source... Go to PubMed...
    12. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006 Jan 20; 24(3): 467-475. Go to original source... Go to PubMed...
    13. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer. 2008 May 1; 112(9): 1949-1953. Go to original source... Go to PubMed...
    14. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005 Dec 20; 23(36): 9130-9137. Go to original source... Go to PubMed...
    15. Sagstuen H, Aass N, Foss? SD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol. 2005 Aug 1; 23(22): 4980-4990. Go to original source... Go to PubMed...
    16. Nord C, Foss? SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer. 2003 Jan 13; 88(1): 36-41. Go to original source... Go to PubMed...
    17. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007 Oct 1; 25(28): 4370. Go to original source... Go to PubMed...
    18. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996 Nov; 14(11): 2923-2932. Go to original source... Go to PubMed...
    19. Tanaka H, Ishikawa E, Teshima S, et al. Histopathological study of human cisplatin nephropathy. Toxicol Pathol. 1986; 14(2): 247-257. Go to original source... Go to PubMed...
    20. Verheij M, Dewit LG, Valdes Olmos RA, et al. Evidence for a renovascular component in hypertensive patients with late radiation nephropathy. Int J Radiat Oncol Biol Phys. 1994; 30(3): 677-683. Go to original source... Go to PubMed...
    21. Mulla MG, Ananthkrishnan G, Mirza MS, et al. Renal artery stenosis after radiotherapy for stage I seminoma, a case report. Clin Oncol. 2007; 19(3): 209-211. Go to original source... Go to PubMed...
    22. Aass N, Foss? SD, Aas M, Lindegaard MW. Renal function related to different treatment modalities for malignant germ cell tumours. Br J Cancer. 1990 Nov; 62(5): 842-846. Go to original source... Go to PubMed...
    23. Foss? SD, Aass N, Winderen M, Börmer OP, Olsen DR. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol. 2002 Feb; 13(2): 222-228. Go to original source... Go to PubMed...
    24. Barton C, Duchesne G, Williams M, Fisher C, Horwich A. The impact of hydronephrosis on renal function in patients treated with cisplatin-based chemotherapy for metastatic nonseminomatous germ cell tumors. Cancer. 1988 Oct 1; 62(7): 1439-1443. Go to original source...
    25. Astor BC, Hallan SI, Miller ER III, et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008; 167(10): 1226-1234. Go to original source... Go to PubMed...
    26. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010 Sep 30; 341: 4986. Go to original source... Go to PubMed...
    27. Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, Zoungas S, Lambers Heerspink HJ, Chalmers J, Zanchetti A. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010 Sep 14; 56(12): 956-965. Go to original source... Go to PubMed...
    28. Hansen SW. Late-effects after treatment for germ-cell cancer with cisplatin, vinblastine, and bleomycin. Dan Med Bull. 1992 Oct; 39(5): 391-399.
    29. O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003 Jan; 14(1): 91-96. Go to original source... Go to PubMed...
    30. Bredenfeld H, Franklin J, Nogova L, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004 Jun 15; 22(12): 2424-2429. Go to original source... Go to PubMed...
    31. Strumberg D, Brügge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol. 2002 Feb; 13(2): 229-236. Go to original source... Go to PubMed...
    32. Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, Dearnaley DP. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005 Jul 25; 93(2): 200-2007. Go to original source... Go to PubMed...
    33. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C. Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer. 1999 May; 80(5-6): 801-807. Go to original source... Go to PubMed...
    34. Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer. J Clin Oncol. 1997 Apr; 15(4): 1444-1448. Go to original source... Go to PubMed...
    35. Foss? SD, Theodorsen L, Norman N, Aabyholm T. Recovery of impaired pretreatment spermatogenesis in testicular cancer. Fertil Steril. 1990 Sep; 54(3): 493-496. Go to original source... Go to PubMed...
    36. Jonker-Pool G, Van de Wiel H, Hoekstra H, Sleijfer D, Van-Driel M, Van-Basten J, Koops H. Sexual functioning after treatment for testicular cancer - review and meta-analysis of 36 empirical studies between 1975-2000. Arch Sexual Behav. 2001; 301: 55-74. Go to original source... Go to PubMed...
    37. Fegg MJ, Gerl A, Vollmer TC, Gruber U, Jost C, Meiler S, Hiddemann W. Subjective quality of life and sexual functioning after germ-cell tumour therapy. Br J Cancer. 2003 Dec 15; 89(12): 2202-2206. Go to original source... Go to PubMed...
    38. Foss? SD, Silde J, Theodorsen L, Pettersen EO. Pre-treatment DNA ploidy of sperm cells as a predictive parameter of post-treatment spermatogenesis in patients with testicular cancer. Br J Urol. 1994 Sep; 74(3): 359-365. Go to original source... Go to PubMed...
    39. Gandini L, Sgr? P, Lombardo F, Paoli D, Culasso F, Toselli L, Tsamatropoulos P, Lenzi A. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod. 2006 Nov; 21(11): 2882-2889. Go to original source... Go to PubMed...
    40. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr. 2005; (34): 12-17. Go to original source... Go to PubMed...
    41. Howell SJ, Shalet SM. Effect of cancer therapy on pituitarytesticular axis. Int J Androl. 2002 Oct; 25(5): 269-276. Go to original source... Go to PubMed...
    42. Huyghe E, Matsuda T, Daudin M, Chevreau C, Bachaud JM, Plante P, Bujan L, Thonneau P. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer. 2004 Feb 15; 100(4): 732-737. Go to original source... Go to PubMed...
    43. Bryd?y M, Foss? SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O. Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005 Nov 2; 97(21): 1580-1588. Go to original source... Go to PubMed...
    44. Matos E, Skrbinc B, Zakotnik B. Fertility in patients treated for testicular cancer. J Cancer Surviv. 2010 Sep; 4(3): 274-278. Go to original source... Go to PubMed...
    45. Jacobsen KD, Ous S, Waehre H, Trasti H, Stenwig AE, Lien HH, Aass N, Foss? SD. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer. 1999 Apr; 80(1-2): 249-255. Go to original source... Go to PubMed...
    46. Foss? SD, Almaas B, Jetne V, Bjerkedal T. Paternity after irradiation for testicular cancer. Acta Radiol Oncol. 1986 JanFeb; 25(1): 33-36. Go to original source... Go to PubMed...
    47. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006 Dec; 27(6): 992-1002. Go to original source... Go to PubMed...
    48. Glendenning JL, Barbachano Y, Norman AR, et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. 2010 May 15; 116(10): 2322-2331. Go to original source... Go to PubMed...
    49. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs. 1995 Jun; 6(3): 369-383. Go to original source... Go to PubMed...
    50. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005 Jan 11; 64(1): 26-31. Go to original source... Go to PubMed...
    51. Schagen SB, Boogerd W, Muller MJ, Huinink WT, Moonen L, Meinhardt W, Van Dam FS. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 2008; 47(1): 63-70. Go to original source... Go to PubMed...
    52. Pedersen AD, Rossen P, Mehlsen MY, Pedersen CG, Zachariae R, von der Maase H. Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc. 2009 Mar; 15(2): 296-301. Go to original source... Go to PubMed...
    53. Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L, Gritz ER. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer. 2011 Jan 1; 117(1): 190-196. Go to original source... Go to PubMed...
    54. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 1999 Dec 10; 83(6): 866-869. Go to original source... Go to PubMed...
    55. Aass N, Kaasa S, Lund E, Kaalhus O, Heier MS, Foss? SD. Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer. 1990 Jan; 61(1): 151-155. Go to original source... Go to PubMed...
    56. Shinn EH, Swartz RJ, Thornton BB, Spiess PE, Pisters LL, Basen-Engquist KM. Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls. J Clin Oncol. 2010 May 1; 28(13): 2274-2279. Go to original source... Go to PubMed...
    57. Hentrich M, Fegg MJ, Meiler S, Jost C, Gerl A. Smoking cessation in long-term survivors of germ cell tumour. J Cancer Res Clin Oncol. 2006 Sep; 132(9): 557-560. Go to original source... Go to PubMed...
    58. Shinn EH, Basen-Engquist K, Thornton B, Spiess PE, Pisters L. Health behaviors and depressive symptoms in testicular cancer survivors. Urology. 2007 Apr; 69(4): 748-753. Go to original source... Go to PubMed...
    59. Mužík J, Abrahámová J, Büchler T, Dušek L. Epidemiologie zhoubného novotvaru varlete (C62) v České republice. In: Abrahámová J. Vybrané otázky onkologie XV, Galén, Praha 2011. Pp 12-14.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.